Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The metabolism, classification, biomedical implication and clinical application of polyunsaturated fatty acids (PUFAs) were analyzed. It was proved that PUFAs class omega-3 have positive effects on cardiovascular system. First of all, this is an antiarrhythmogenic action, which is accompanied by the increase in variability of heart rhythm. Omega-3 PUFAs cause the reduction in platelet activity and vasoactive mediator release (serotonin, thromboxane A2), vasodilatation, the reduction in inflammatory mediators release and endothelium permeability, the rising of endothelium dependent dilatation of vessels, the depression of vascular response on angiotensine П and noradrenalin. Omega-3 PUFAs are responsible for the reduction in blood pressure, the increase in erythrocytes elasticity, the fall of fibrinogen concentration and normalization of plasma lipid profile. Omega-3 PUFAs in large dozes show antiatherosclerotic effect. Clinical data showing that Omega-3 PUFAs increase in life time due to reduction in sudden death incidence were provided. It is suggested to use Omega-3 PUFAs (OMAKOR) for secondary prevention of ischemic heart disease and treatment of hypertriglyceridemia.

About the Authors

A. I. Martinov
Moscow State University of Medicine and Stomatology
Russian Federation
Chair of hospital therapy №1, Medical Faculty

V. L. Chomenko
Moscow State University of Medicine and Stomatology
Russian Federation
Chair of hospital therapy №1, Medical Faculty


1. Lampe F.C., Whincup P.H., Wannamethee S.G., et al. The natural history of prevalent ischaemic heart disease in middle-aged men. Eur. Heart J. 2000; 21: 1052-1062

2. Marchioli R., Rupp H. Высокоочищенные омега-3-жирные кислоты как средство вторичной профилактики инфаркта миокарда. Москва 2006: 1-81

3. Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of csrdiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356(9237): 1213 – 1218

4. Albert C.M., Hennekens C.H., O’Donnell C.J., et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23-28

5. Chin J.P., Dart A.M. How do fish oils affect vascular function? Clin. Exp. Pharmacol. Physiol. 1995; 22:71-81

6. Sellmayer A., Witzgall H., Lorenz R.L., Weber P.C. Effects of dietary fish oil on ventricular premature complexes. Am. J. Cardiol. 1995; 76: 974-977

7. Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2(8666): 757-761

8. Kris–Etherton P.M., Taylor D.S., Yu-Poth S., et al. Polyunsaturated fatty acids in the food chain in the United States. Am. J. Clin. Nutr. 2000; 71 (1 Suppl.): 179S-188S

9. Marckmann P., Bladbjerg E.M., Jespersen J. Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Artherioscler. Thromb. Vasc. Biol. 1997; 17: 3384-3391

10. Marchioli R., Barzi F ., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)- Prevenzione. Circulation 2002; 105: 1897-1903

11. Albert C.M., Campos H., Stampfer M.J., et al. Blood levels of long- chain n-3 fatty acids and the risk of sudden death. N Engl J. Med. 2002; 346: 1113-1118

12. Christensen J.H., Korup E., Aaroe J., et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am.J. Cardi- ol., 1997; 79: 1670-1673

13. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk patients after myocardial infarction. N.Engl.J.Med. 1998; 339: 489-497

14. Task Force on Sudden cardiac Death of the European Society of Cardiology. Eur. Heart J. 2001; 22: 1374-1450

15. Stephens N.G., Parsons A., Schofield P.M., et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347(9004): 781 – 786

16. Siscovick D.S., Raghunathan T.E., King I., et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274: 1363-1367

17. Antithrombotic. Trialist’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86

18. Jha P, Flather M., Lonn E., et al. The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann. Intern. Med. 1995; 123: 860-872

19. Mehta R.H., Eagle K.A. Secondary prevention in acute myocardial infarction. BMJ 1998; 316: 838-842

20. Stein P.K., Kleiger R.E. Insights from the study of heart rate variability. Annu. Rev. Med. 1999; 50: 249-261

For citation:

Martinov A.I., Chomenko V.L. NEW EVIDENCES OF POSSIBILITY OF OMEGA-3 ACIDS USE FOR MYOCARDIAL INFARCTION SECONDARY PREVENTION. Rational Pharmacotherapy in Cardiology. 2006;2(3):65-68. (In Russ.)

Views: 376

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)